Previous 10 | Next 10 |
Data from study on Tumor Treating Fields in combination with anti-PD-1 therapy published in Cancer Immunology, Immunotherapy Novocure (NASDAQ: NVCR) announced today that preclinical data on Tumor Treating Fields in combination with anti-PD-1 therapy were published in the peer-reviewe...
Image source: The Motley Fool. NovoCure Limited (NASDAQ: NVCR) Q4 2019 Earnings Call Feb 27, 2020 , 1:30 p.m. ET Ashley Cordova -- Senior Vice President of Finance and Investor Relations Continue reading
In response to the reported fourth-quarter and full-year results, shares of NovoCure (NASDAQ: NVCR) , a high-growth medical device company that is focused on cancer, fell as much as 12% in early-morning trading on Thursday. The stock eventually recovered and was down about 2% as of 3:0...
NovoCure Limited (NVCR) Q4 2019 Earnings Conference Call February 27, 2020 8:00 AM ET Company Participants Ashley Cordova - Senior Vice President of Finance & Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Wilco Groenhuysen - C...
Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...
The following slide deck was published by NovoCure Limited in conjunction with their 2019 Q4 earnings Read more ...
NovoCure (NASDAQ: NVCR ): Q4 GAAP EPS of $0.04 beats by $0.02 . More news on: NovoCure Limited, Earnings news and commentary, Healthcare stocks news, Read more ...
Quarterly net revenues of $99.2 million, representing 42 percent growth versus the fourth quarter 2018 and 8 percent growth versus the third quarter 2019 Second quarter of positive net income with $0.04 in earnings per share Four phase 3 pivotal clinical trials ongoing creating t...
Safety First: NASCAR driver Johanna Long and her helmet (Credit: Gearheads ) Revisiting Our Revised Security Selection Method Since June 2017, I've run a Marketplace service which has an " investing with a helmet on " approach: I present concentrated portfolios where each security is he...
Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...